Do GLP-1 Drugs Like Semaglutide Worsen Eye Problems in Diabetes? A Closer Look at the Evidence

This is a narrative review synthesizing relevant publications including meta-analyses, randomized controlled trials, post hoc analyses, and preclinical in vitro and in vivo research. The literature search used WorldCat Discovery, PubMed, and Google Scholar databases. The review evaluated both the diabetic retinopathy and NAION associations separately.

With tens of millions of people now taking GLP-1 drugs, even a small increase in eye complication risk could affect enormous numbers of patients. Many people taking these drugs for diabetes already have retinopathy or are at risk for it. Clinicians need clear guidance on whether to screen more aggressively, adjust dosing speed, or warn patients about eye risks. This review helps separate genuine safety signals from the expected consequences of rapid blood sugar improvement.

This controversy highlights a broader challenge with the GLP-1 agonist revolution: as these drugs are prescribed to increasingly large populations for both diabetes and obesity, rare or subtle adverse effects may emerge that were not apparent in clinical trials. The distinction between drug-caused harm and expected physiological consequences of effective treatment (like early worsening of retinopathy with any rapid glucose improvement) is critical for making sound prescribing decisions. Similar safety surveillance questions are arising for GLP-1 drugs across multiple organ systems.

As a narrative review, this does not use systematic methodology or quantitative meta-analysis. The evidence base for both associations is relatively limited — most retinopathy data comes from post hoc analyses of trials not designed to study eye outcomes, and NAION evidence is largely from case reports and observational studies with significant confounders. The review cannot definitively rule out a causal relationship for either condition. Publication bias may affect the available literature in both directions.